These results signify that modification of IFN-γ signaling via PD1 blockade can improve CAR T-cell therapy against EphA2-b-expressing gliomas, reiterating the importance of maintaining a delicate balance of cytokine levels for an effective therapeutic response. Here, IFNG is linked to central nervous system cancer.